Clinical trial Phase 3 Interventional Ages 18 and up

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Run by Viking Therapeutics, Inc. · NCT07104383 · Data updated 2026-11-12

Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2027-07-01.

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight

Research outlook What's coming for Type 2 diabetes: the next 6 months to 5 years

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment1100 (estimated)
SponsorViking Therapeutics, Inc.
Industry-sponsored
Drugs / interventionsVK2735
Locations127 sites (Puerto Rico, United States)
Trial IDNCT07104383 on ClinicalTrials.gov

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥18 years of age at the time of signing the informed consent
2. Body mass index (BMI) ≥27 kg/m2
3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Type 2 diabetes mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists

Exclusion Criteria:

1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
2. Self-reported body weight change of 5% or more within 3 months of screening
3. Have a prior or planned surgical treatment for obesity (except for liposuction or abdominoplasty if performed \>1 year prior to screening)
4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
5. Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 diabetes mellitus (T2DM)
6. Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening

   • Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG \< 54 mg/dL
7. Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values \> 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization
8. Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment
9. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
10. History of acute or chronic pancreatitis
11. Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening

Where it's running

  • Viking Clinical Site #2037
    Birmingham, Alabama, United States
  • Viking Clinical Site #2064
    Birmingham, Alabama, United States
  • Viking Clinical Site #2128
    Huntsville, Alabama, United States
  • Viking Clinical Site #2005
    Chandler, Arizona, United States
  • Viking Clinical Site #2017
    Flagstaff, Arizona, United States
  • Viking Clinical Site #2018
    Peoria, Arizona, United States
Show 44 more locations
  • Viking Clinical Site #2135
    Scottsdale, Arizona, United States
  • Viking Clinical Site #2019
    Tucson, Arizona, United States
  • Viking Clinical Site #2036
    Little Rock, Arkansas, United States
  • Viking Clinical Site #2071
    Chula Vista, California, United States
  • Viking Clinical Site #2070
    Escondido, California, United States
  • Viking Clinical Site #2054
    Huntington Park, California, United States
  • Viking Clinical Site #2014
    Lake Forest, California, United States
  • Viking Clinical Site #2129
    Lemon Grove, California, United States
  • Viking Clinical Site #2051
    Lincoln, California, United States
  • Viking Clinical Site #2050
    Long Beach, California, United States
  • Viking Clinical Site #2078
    Manteca, California, United States
  • Viking Clinical Site #2053
    Montclair, California, United States
  • Viking Clinical Site #2068
    Panorama City, California, United States
  • Viking Clinical Site #2132
    Rolling Hills Estates, California, United States
  • Viking Clinical Site #2131
    San Diego, California, United States
  • Viking Clinical Site #2052
    Spring Valley, California, United States
  • Viking Clinical Site #2109
    Tustin, California, United States
  • Viking Clinical Site #2067
    Van Nuys, California, United States
  • Viking Clinical Site #2079
    Walnut Creek, California, United States
  • Viking Clinical Site #2119
    Denver, Colorado, United States
  • Viking Clinical Site #2013
    Clearwater, Florida, United States
  • Viking Clinical Site #2121
    Clearwater, Florida, United States
  • Viking Clinical Site #2003
    Cooper City, Florida, United States
  • Viking Clinical Site #2112
    DeLand, Florida, United States
  • Viking Clinical Site #2107
    Delray Beach, Florida, United States
  • Viking Clinical Site #2083
    Fort Myers, Florida, United States
  • Viking Clinical Site #2058
    Jacksonville, Florida, United States
  • Viking Clinical Site #2076
    Lakeland, Florida, United States
  • Viking Clinical Site #2060
    Lakewood Rch, Florida, United States
  • Viking Clinical Site #2117
    Miami, Florida, United States
  • Viking Clinical Site #2012
    Ocoee, Florida, United States
  • Viking Clinical Site #2056
    Palmetto Bay, Florida, United States
  • Viking Clinical Site #2011
    Port Orange, Florida, United States
  • Viking Clinical Site #2057
    West Palm Beach, Florida, United States
  • Viking Clinical Site #2116
    Atlanta, Georgia, United States
  • Viking Clinical Site #2030
    Columbus, Georgia, United States
  • Viking Clinical Site #2120
    Rincon, Georgia, United States
  • Viking Clinical Site #2093
    Savannah, Georgia, United States
  • Viking Clinical Site #2025
    Woodstock, Georgia, United States
  • Viking Clinical Site #2062
    Honolulu, Hawaii, United States
  • Viking Clinical Site #2080
    Meridian, Idaho, United States
  • Viking Clinical Site #2006
    Chicago, Illinois, United States
  • Viking Clinical Site #2146
    Indianapolis, Indiana, United States
  • Viking Clinical Site #2127
    Valparaiso, Indiana, United States

+77 more sites. See ClinicalTrials.gov for the full list.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.